Samar H. Abbas

1.0k total citations
35 papers, 790 citations indexed

About

Samar H. Abbas is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, Samar H. Abbas has authored 35 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Organic Chemistry, 22 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Samar H. Abbas's work include Synthesis and biological activity (16 papers), Cancer therapeutics and mechanisms (16 papers) and Synthesis and Biological Evaluation (6 papers). Samar H. Abbas is often cited by papers focused on Synthesis and biological activity (16 papers), Cancer therapeutics and mechanisms (16 papers) and Synthesis and Biological Evaluation (6 papers). Samar H. Abbas collaborates with scholars based in Egypt, Japan and United States. Samar H. Abbas's co-authors include Gamal El‐Din A. Abuo‐Rahma, Amer Ali Abd El‐Hafeez, Mohamed Abdel‐Aziz, Abdelfattah Hassan, Dalia Abdelhamid, Elshimaa M. N. Abdelhafez, Heba A. Hassan, Monica M. Montano, Mai E. Shoman and Eman A. M. Beshr and has published in prestigious journals such as RSC Advances, European Journal of Medicinal Chemistry and Current Medicinal Chemistry.

In The Last Decade

Samar H. Abbas

34 papers receiving 782 citations

Peers

Countries citing papers authored by Samar H. Abbas

Since Specialization

Citations

This map shows the geographic impact of Samar H. Abbas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samar H. Abbas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samar H. Abbas more than expected).

Fields of papers citing papers by Samar H. Abbas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samar H. Abbas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samar H. Abbas. The network helps show where Samar H. Abbas may publish in the future.

Co-authorship network of co-authors of Samar H. Abbas

This figure shows the co-authorship network connecting the top 25 collaborators of Samar H. Abbas. A scholar is included among the top collaborators of Samar H. Abbas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samar H. Abbas. Samar H. Abbas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors 2025 ·Bioorganic Chemistry ·(unknown), Samar H. Abbas, Ahmed M. Sayed, Hesham A. M. Gomaa, Bahaa G. M. Youssif, Dalia Abdelhamid, Mohamed Abdel‐Aziz	4
2	A novel approach for apoptosis and caspase-3 inhibition using new candidates of 1,5-Diaryl triazole-3-carboxamides 2024 ·(unknown), Elshimaa M. N. Abdelhafez, Samar H. Abbas, (unknown), Walaa Yehia Abdelzaher, Omar M. Aly	0
3	Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma 2024 ·Archiv der Pharmazie ·(unknown), Asmaa M. AboulMagd, Samar H. Abbas, Mohamed Abdel‐Aziz, Hamdy M. Abdel‐Rahman	7
4	Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapy 2024 ·European Journal of Medicinal Chemistry ·(unknown), Samar H. Abbas, Hiroshi Tateishi, (unknown), (unknown), Akihiro Ito, Mikako Fujita, Masami Otsuka, Mohamed Abdel‐Aziz, Mohamed O. Radwan	3
5	New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors 2024 ·Bioorganic Chemistry ·(unknown), Amer Ali Abd El‐Hafeez, Taha F. S. Ali, Ahmed M. Sayed, Heba Ali Hassan, Eman A. M. Beshr, Samar H. Abbas	4
6	The significance of quinazoline derivatives as potential multi-target anti-cancer agents: review article 2023 ·(unknown), Samar H. Abbas, (unknown), Hamdy M. Abdel‐Rahman, M.S. Osman	1
7	Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review 2023 ·RSC Advances ·(unknown), Asmaa M. AboulMagd, Samar H. Abbas, Hamdy M. Abdel‐Rahman, Mohamed Abdel‐Aziz	35
8	Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia 2023 ·BMC Chemistry ·(unknown), Taha F. S. Ali, Samar H. Abbas, Heba A. Hassan, Eman A. M. Beshr	13
9	Chalcone/1,3,4-Oxadiazole/Benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting EGFR & BRAFV600E 2023 ·BMC Chemistry ·(unknown), Samar H. Abbas, Hesham A. M. Gomaa, Bahaa G. M. Youssif, Ahmed M. Sayed, Dalia Abdelhamid, Mohamed Abdel‐Aziz	18
10	The main biotargets of indole or 2-oxoindole-based hybrids acting as promising antiproliferative agents 2023 ·Heba A. Hassan, Samar H. Abbas, Eman A. M. Beshr, (unknown), Taha F. S. Ali	3
11	New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization 2023 ·Molecular Diversity ·(unknown), Taha F. S. Ali, Samar H. Abbas, Ahmed M. Sayed, Eman A. M. Beshr, Heba A. Hassan	20
12	Derivatives contain dimethylaminopyridine as SIRT2 inhibitors: A mini review 2023 ·(unknown), Samar H. Abbas, Mikako Fujita, M.S. Osman	1
13	Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors 2022 ·Molecular Diversity ·(unknown), (unknown), Mohamed Badr, (unknown), (unknown), (unknown), (unknown), (unknown), Alaa M. Hayallah, Samar H. Abbas, Gamal El‐Din A. Abuo‐Rahma	16
14	Novel urea linked ciprofloxacin-chalcone hybrids having antiproliferative topoisomerases I/II inhibitory activities and caspases-mediated apoptosis 2020 ·Bioorganic Chemistry ·(unknown), Samar H. Abbas, Alaa M. Hayallah, Gamal El‐Din A. Abuo‐Rahma, Yaser A. Mostafa	28
15	Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity 2019 ·Bioorganic Chemistry ·(unknown), Elshimaa M. N. Abdelhafez, Samar H. Abbas, Gamal A. I. Moustafa, Glenn Hauk, James M. Berger, Satoshi Mitarai, Masayoshi Arai, Rehab Mahmoud Abd El-Baky, Gamal El‐Din A. Abuo‐Rahma	26
16	1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities 2018 ·Bioorganic Chemistry ·(unknown), Amer Ali Abd El‐Hafeez, Dalia Abdelhamid, Samar H. Abbas, Monica M. Montano, Mohamed Abdel‐Aziz	60
17	New 1,2,4-triazole-Chalcone hybrids induce Caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells 2018 ·European Journal of Medicinal Chemistry ·(unknown), Amer Ali Abd El‐Hafeez, Samar H. Abbas, Dalia Abdelhamid, Mohamed Abdel‐Aziz	76
18	New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity 2018 ·Bioorganic Chemistry ·Samar H. Abbas, Amer Ali Abd El‐Hafeez, Mai E. Shoman, Monica M. Montano, Heba A. Hassan	52
19	Synthesis, cytotoxic activity, and tubulin polymerization inhibitory activity of new pyrrol-2(3H)-ones and pyridazin-3(2H)-ones 2016 ·Bioorganic Chemistry ·Samar H. Abbas, Gamal El‐Din A. Abuo‐Rahma, Mohamed Abdel‐Aziz, Omar M. Aly, Eman A. M. Beshr, Amira M. Gamal‐Eldeen	29
20	New antiproliferative 7-(4-(N-substituted carbamoylmethyl)piperazin-1-yl) derivatives of ciprofloxacin induce cell cycle arrest at G2/M phase 2016 ·Bioorganic & Medicinal Chemistry ·(unknown), Amer Ali Abd El‐Hafeez, Samar H. Abbas, Elshimaa M. N. Abdelhafez, Gamal El‐Din A. Abuo‐Rahma	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact